Heterocyclic Compound For Inducing Degradation Of G12 D Mutant Kras

< Back

Heterocyclic Compound For Inducing Degradation Of G12 D Mutant Kras Protein

Abstract: To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compounds represented by formula (I) and formula (A) have an excellent action for inducing the degradation of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #

Filing Date

10 September 2024

Publication Number

52/2024

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ASTELLAS PHARMA INC.

5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Inventors

1. YOSHINARI, Tomohiro

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

2. KAWAGUCHI, Kenichi

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

3. KAWAMINAMI, Eiji

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

4. ISHIOKA, Hiroki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

5. WATANABE, Hideyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

6. IMAIZUMI, Tomoyoshi

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

7. HAMAGUCHI, Hisao

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

8. TAKAHASHI, Fumie

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

9. MORIKAWA, Takahiro

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

10. KURAMOTO, Kazuyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

11. NAGASHIMA, Takeyuki

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

12. INAMURA, Kohei

c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Specification

Documents

Application Documents

#	Name	Date
1	202447068178-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [10-09-2024(online)].pdf	2024-09-10
2	202447068178-STATEMENT OF UNDERTAKING (FORM 3) [10-09-2024(online)].pdf	2024-09-10
3	202447068178-REQUEST FOR EXAMINATION (FORM-18) [10-09-2024(online)].pdf	2024-09-10
4	202447068178-PROOF OF RIGHT [10-09-2024(online)].pdf	2024-09-10
5	202447068178-PRIORITY DOCUMENTS [10-09-2024(online)].pdf	2024-09-10
6	202447068178-FORM 18 [10-09-2024(online)].pdf	2024-09-10
7	202447068178-FORM 1 [10-09-2024(online)].pdf	2024-09-10
8	202447068178-DECLARATION OF INVENTORSHIP (FORM 5) [10-09-2024(online)].pdf	2024-09-10
9	202447068178-COMPLETE SPECIFICATION [10-09-2024(online)].pdf	2024-09-10
10	202447068178-FORM-26 [11-09-2024(online)].pdf	2024-09-11
11	202447068178-FORM 3 [20-02-2025(online)].pdf	2025-02-20